Novo Holdings has made a €86 million investment in 21st.Bio, a Danish bioindustrial scale-up company.
21st.Bio supports bioindustrial companies with matters such as the upscaling of molecular innovation or large-scale production that can meet market demands and advance the green transition globally.
One core focal area for 21st.Bio is producing proteins and peptides that can be utilised for the food, materials and agricultural industries.
21st.Bio’s technology platform originates from selected parts of Novozymes, which provides a co-exclusive license to 21st.Bio within certain boundaries of applications.
Access to selected parts of Novozymes’ R&D platform and the investment by Novo Holdings will enable the company to expand its capabilities even further.
Thomas Schmidt, co-founder and CEO of 21st.Bio, said: “Many brilliant industrial biotech ideas never succeed, because production challenges result in too high price points for the final product. Hence, a vast number of otherwise great innovations do not make it to a scale at which they are truly relevant for the world”.
He continued: “At 21st.Bio, we can help establish the right technology for producing novel molecules and peptides and hence help innovators successfully make the difficult step from innovation to big business and impact for the planet. We have gained access to a selection of Novozymes’ unique technology platform on commercial terms, which means that a success for 21st.Bio is also a success for Novozymes.”
Søren Møller, managing partner of Novo Seeds at Novo Holdings, will join the company’s board of directors.
By Lauren Ford
Source: foodbev.com
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
